Ken Griffin
APRE icon

Ken Griffin’s Aprea Therapeutics APRE Stock Holding History

Ken Griffin’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,041
Closed -$43.5K – 12922
2025
Q4 		$43.5K Buy
+51,041
New +$62.7K ﹤0.01% 12095
2025
Q2 		– Sell
-30,083
Closed -$61.4K – 12423
2025
Q1 		$61.4K Buy
+30,083
New +$94.2K ﹤0.01% 12088
2023
Q1 		– Sell
-64
Closed -$411 – 14668
2022
Q4 		$411 Buy
+64
New +$675 ﹤0.01% 14664
2022
Q3 		– Sell
-944
Closed -$16.8K – 12543
2022
Q2 		$14K Sell
944
-2,910
-76% -$67.1K ﹤0.01% 12509
2022
Q1 		$143K Sell
3,854
-4,309
-53% -$177K ﹤0.01% 11903
2021
Q4 		$469K Buy
8,163
+2,066
+34% +$183K ﹤0.01% 9858
2021
Q3 		$623K Buy
6,097
+4,666
+326% +$424K ﹤0.01% 9335
2021
Q2 		$140K Buy
+1,431
New +$132K ﹤0.01% 12565
2020
Q4 		– Sell
-3,704
Closed -$1.78M – 10873
2020
Q3 		$1.78M Sell
3,704
-11,743
-76% -$6.57M ﹤0.01% 4925
2020
Q2 		$12M Sell
15,447
-615
-4% -$404K ﹤0.01% 2021
2020
Q1 		$11.2M Buy
16,062
+611
+4% +$448K 0.01% 1742
2019
Q4 		$14.2M Buy
+15,451
New +$8.51M 0.01% 1837

Other funds holding APRE

ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ken Griffin's APRE Position: Q1 2026 in Review

Ken Griffin sold out of Aprea Therapeutics (APRE) in Q1 2026, closing a stake of 51,041 shares — an estimated $43.5K sold.

Ken Griffin first reported a position in APRE in Q4 2019 and held it in 12 quarters. The position peaked at $14.2M in Q4 2019. 22 funds tracked by Wall St. Rank hold APRE as of Q1 2026.

  • Ken Griffin reported no remaining Aprea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ken Griffin sold 51,041 Aprea Therapeutics shares in Q1 2026, an estimated $43.5K.
  • Ken Griffin first reported a position in Aprea Therapeutics in Q4 2019 and held it in 12 quarters.
  • Ken Griffin's Aprea Therapeutics position peaked at $14.2M in Q4 2019.
  • 22 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.